Magnesium research · 2009
Effect of MgSO₄ on FEV₁ in stable severe asthma patients with chronic airflow limitation.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zandsteeg Alinda M G, Hirmann Petra, Pasma Henk R, Yska Jan-Peter, ten Brinke Anneke
Аннотация
RATIONALE: The bronchodilating potency of magnesium sulphate (MgSO₄) has been shown in acute asthma exacerbations. We hypothesized that smooth muscle cell relaxation by magnesium might also be beneficial in chronic severe asthma with persistent airflow limitation.
AIM: To investigate whether nebulised magnesium, administered according to a dosing scheme shown to be effective in acute asthma, induces bronchodilation in stable asthma patients with persistent airflow limitation.
METHODS: In a placebo-controlled, cross-over study, 13 severe asthma patients with postbronchodilator FEV₁ < 75% predicted received either 2.5 mL MgSO₄ 6.4% or placebo in 3 nebulisations at 30 minute intervals. Before the first and 30 minutes after the last inhalation FEV₁, exhaled nitric oxide (NO) in dyspnoea (Borg) were measured.
RESULTS: After MgSO₄ treatment no improvement in FEV₁ occurred (56.2 ± 16.8 to 55.4 ± 17.4% predicted [p = 0.5]), neither was a change in exhaled NO or Borg observed (p > 0.1). The changes in FEV₁, NO or Borg were not different between the treatment arms (p ≥ 0.09).
CONCLUSION: Short-term treatment with magnesium inhalations had no direct bronchodilating effect in stable severe asthma patients with persistent airflow limitation. Yet, clinical observations suggest a heterogeneity in response, probably related to treatment intensity, and support further exploration of magnesium administration in these patients.
AIM: To investigate whether nebulised magnesium, administered according to a dosing scheme shown to be effective in acute asthma, induces bronchodilation in stable asthma patients with persistent airflow limitation.
METHODS: In a placebo-controlled, cross-over study, 13 severe asthma patients with postbronchodilator FEV₁ < 75% predicted received either 2.5 mL MgSO₄ 6.4% or placebo in 3 nebulisations at 30 minute intervals. Before the first and 30 minutes after the last inhalation FEV₁, exhaled nitric oxide (NO) in dyspnoea (Borg) were measured.
RESULTS: After MgSO₄ treatment no improvement in FEV₁ occurred (56.2 ± 16.8 to 55.4 ± 17.4% predicted [p = 0.5]), neither was a change in exhaled NO or Borg observed (p > 0.1). The changes in FEV₁, NO or Borg were not different between the treatment arms (p ≥ 0.09).
CONCLUSION: Short-term treatment with magnesium inhalations had no direct bronchodilating effect in stable severe asthma patients with persistent airflow limitation. Yet, clinical observations suggest a heterogeneity in response, probably related to treatment intensity, and support further exploration of magnesium administration in these patients.